9 results
Systemic Lupus Erythematosus (SLE) - Diagnosis and Management Summary
 • Epidemiology: 10-180/100,000, Typically Age 20-40, F:M
Systemic Lupus Erythematosus ... Manifestations: Malar rash ... Positive in 60-80% of cases ... life-threatening • Treatment ... #Summary #rheumatology
CNS Manifestations of Systemic Lupus Erythematosus (SLE)

Clinical Manifestations: Demyelinating Syndrome, Headache, Movement disorders, Seizure disorders, Aseptic
(SLE) Clinical ... autoantibodies that will cause ... #SLE #CNS #neurology ... #rheumatology # ... cerebritis #diagnosis #management
Drug Induced Lupus vs SLE
Drug Induced Lupus (DIL):
 • Epidemiology: -10% of all lupus cases, drug-dependent,
NPSLE rare, Malar rash ... Systemic Lupus Erythematosus ... Manifestations: Malar rash ... comparison #table #rheumatology ... #diagnosis #management
Macrophage Activation Syndrome (MAS)
Classified among the secondary or acquired forms of haemophagocytic lymphohistiocytosis (sHLH)

What?
A subset of
Petechial or purpuric rash ... [SLE], AOSD) • ... Treatment: • Corticosteroids ... Syndrome #Diagnosis #Management ... #Hematology #Rheumatology
Myasthenia Gravis Overview

Myasthenia Gravis is an autoimmune disorder of the postsynaptic neuromuscular junction.  Ab to
rheumatoid arthritis, SLE ... Myasthenia Crises ... immunosuppressants - Meds ... Gravis #diagnosis #management ... #neurology
Giant cell arteritis (GCA)

Giant cell arteritis (GCA) definition: Most common systemic inflammatory vasculitis in older adults
with systemic, neurologic ... (Cornelia NEJM ... Treatment of GCA ... them, but urgent rheumatology ... Symptoms #Diagnosis #Management
Vasculitis - Differential Diagnosis Framework

When to Consider Vasculitis:
• Purpura, ischemic skin lesions
• Mononeuritis multiplex
• Hematuria, proteinuria,
diseases, such as SLE ... ischemia • Skin: Erythematous ... , mucositis • Rash ... tract, and often causes ... Differential #Diagnosis #Rheumatology
Drug Induced Lupus (DIL)
 • Epidemiology: -10% of all lupus cases, drug-dependent, 4:1 to 1:1 F:M
NPSLE rare, Malar rash ... is rare in DIL, SCLE-DIL ... Discontinuation of causal ... DrugInduced #Lupus #DIL #rheumatology ... #management
Anti-NXP-2 Dermatomyositis

What?
DM with generalized subcutaneous edema
Pts have more myalgias, more severe weakness, and an increased prevalence
rash on the face ... Muscle atrophy may cause ... positive patients Treatment ... Dermatomyositis #diagnosis #management ... #rheumatology #